Cargando…
Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer
Chemotherapy has been reported to increase the proportion of cancer stem cells (CSCs) and to promote epithelial-mesenchymal transition (EMT) phenotype changes. Anti-HER2 therapy may provide a strategy for eliminating CSC and EMT, which contribute to therapeutic resistance. No study has determined th...
Autores principales: | Yamauchi, Teruo, Espinosa Fernandez, Jose Rodrigo, Imamura, Chiyo K., Yamauchi, Hideko, Jinno, Hiromitsu, Takahashi, Maiko, Kitagawa, Yuko, Nakamura, Seigo, Lim, Bora, Krishnamurthy, Savitri, Reuben, James M., Liu, Diane, Tripathy, Debasish, Chen, Helen, Takebe, Naoko, Saya, Hideyuki, Ueno, Naoto T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805522/ https://www.ncbi.nlm.nih.gov/pubmed/29467936 http://dx.doi.org/10.18632/oncotarget.23914 |
Ejemplares similares
-
Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells
por: Hosonaga, Mari, et al.
Publicado: (2014) -
HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018) -
PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
por: Lee, Jangsoon, et al.
Publicado: (2021) -
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014) -
Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)